Results 351 to 360 of about 14,957,077 (381)
Some of the next articles are maybe not open access.
C&EN Global Enterprise, 2018
Last August, in a milestone decades in the making, Kymriah became the first cell therapy to be approved by the U.S. Food & Drug Administration. Marketed by the Swiss giant Novartis, Kymriah is made by genetically engineering an individual’s own immune cells to attack a form of leukemia.
openaire +1 more source
Last August, in a milestone decades in the making, Kymriah became the first cell therapy to be approved by the U.S. Food & Drug Administration. Marketed by the Swiss giant Novartis, Kymriah is made by genetically engineering an individual’s own immune cells to attack a form of leukemia.
openaire +1 more source
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.
Journal of the American Medical Association (JAMA)Importance Chimeric antigen receptor (CAR) T cells are T lymphocytes that are genetically engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and causes the T cell to kill the tumor cell.
Jennifer N. Brudno +2 more
semanticscholar +1 more source
Overcoming CAR T cell exhaustion
Nature Reviews Immunology, 2019Overexpression of JUN by CAR T cells renders them resistant to exhaustion and improves tumour control in mouse models, including of solid tumours and of tumours with low levels of antigen expression.
openaire +2 more sources
Best Practice & Research Clinical Haematology, 2018
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal.
openaire +2 more sources
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal.
openaire +2 more sources
MedScien
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors.
openaire +1 more source
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors.
openaire +1 more source
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
New England Journal of MedicineIndolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells.
Metin, Ozdemirli +9 more
openaire +2 more sources
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Nature Medicine, 2022A. Mackensen +23 more
semanticscholar +1 more source
Hematology/Oncology Clinics of North America, 2023
Caron A. Jacobson, Parth S. Shah
openaire +1 more source
Caron A. Jacobson, Parth S. Shah
openaire +1 more source